China’s major new drug Good Manufacturing Practices regulations (GMP 2010) took effect on March 1, 2011. Multinational companies can no longer rely solely upon compliance with U.S. or EU GMP regulations, and will need to review current procedures in China.
This article has been reprinted with the permission of FDLI.